Primary haemochromatosis: a missed cause of chronic fatigue syndrome?
Swinkels, D W, Aalbers, N, Elving, L D et al. · The Netherlands journal of medicine · 2002
Quick Summary
This study examined whether some patients diagnosed with ME/CFS might actually have primary haemochromatosis (a condition where the body absorbs too much iron). Researchers tested blood samples from 88 ME/CFS patients for markers of iron overload and found that iron metabolism markers were elevated in some patients, but genetic testing did not confirm primary haemochromatosis in any of them. The study observed that primary haemochromatosis appears no more common in ME/CFS patients than in the general population—a preliminary finding that has not yet been fully replicated.
Why It Matters
This study addresses whether a treatable metabolic disorder might masquerade as ME/CFS in some patients, which could improve diagnostic accuracy and prevent unnecessary investigation of ME/CFS mechanisms in misdiagnosed individuals. The reassurance that primary haemochromatosis is not overrepresented in ME/CFS cohorts suggests this particular metabolic cause should not be prioritised as a distinctive feature of the condition.
Observed Findings
Elevated transferrin saturation was observed in 19 of 88 (21.6%) ME/CFS patients in initial screening.
On confirmatory testing, persistent elevation of iron parameters was observed in 8 of 11 patients who provided second samples.
No patients carried HFE mutations consistent with primary haemochromatosis (C282Y homozygotes or C282Y-H63D compound heterozygotes).
Estimated prevalence of primary haemochromatosis in this ME/CFS cohort was 2.3% (95% CI 0–5.5%), which was not statistically different from northern European general population estimates (0.25–0.50%).
Inferred Conclusions
The authors interpreted their findings to suggest that primary haemochromatosis is not overrepresented in ME/CFS and therefore is not a common unrecognised cause of ME/CFS misdiagnosis.
They inferred that HFE-related iron overload is unlikely to be a significant contributor to ME/CFS pathophysiology in their population.
The authors noted that isolated elevation of iron metabolism markers without HFE mutations does not constitute primary haemochromatosis and does not indicate a need to pursue haemochromatosis screening in ME/CFS cohorts.
Remaining Questions
Does secondary iron dysregulation (without HFE mutations) occur more frequently in ME/CFS and, if so, what is its functional relevance?
Would screening for primary haemochromatosis yield clinically meaningful diagnoses if applied systematically across larger, more diverse ME/CFS populations?
What This Study Does Not Prove
This study does not establish that iron metabolism is normal in ME/CFS patients—it only excludes primary haemochromatosis as a common mimicker. It does not address whether secondary iron dysregulation or minor variations in iron handling might be associated with ME/CFS pathophysiology. The study does not generalise beyond a single Dutch referral centre or validate whether screening for primary haemochromatosis should be routine in ME/CFS diagnosis.
Tags
Symptom:Fatigue
Biomarker:Blood Biomarker
Method Flag:Weak Case DefinitionNo ControlsSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.